Jonathan Mow named CEO at Veralox
Plus: Ottesen becomes CMO at Adcendo, and updates from Splice Bio, Shape, C4 and more
Veralox Therapeutics Inc. announced it hired Jonathan Mow as CEO and raised $24 million to advance its lead program VLX-1005 into Phase IIa to treat heparin-induced thrombocytopenia. New investors Pappas Capital and NYBC Ventures and existing investors Hatteras Venture Partners, Sanofi Ventures, JDRF T1D Fund and Genesys Capital contributed to the financing. The company also named Pappa’s Peter Young as director and NYBC Ventures’ Meg Wood as observer. Mow was CEO at PhaseBio Pharmaceuticals Inc. (OTCQX:PHASQ) and VP of business development at Amylin Pharmaceuticals.
ADC therapies company Adcendo ApS hired Lone Ottesen as CMO. Ottesen was CMO and chief development officer (CDO) at Circio Holding ASA (OSE:CRNA), and a global clinical head in late-stage clinical development at AstraZeneca plc (LSE:AZN; NASDAQ:AZN)...